spec sheet9 rows
LM22B-10 is a small molecule reported to activate both TrkB and TrkC, the receptors for BDNF and neurotrophin-3, from the same laboratory that produced LM22A-4. ⚠️ Two things about it deserve to come first. Chemically it is a triarylmethane, the same architecture as the leuco forms of malachite green and crystal violet, a class notorious for promiscuous and assay-interfering behaviour. And in recent literature the compound is used almost entirely as a generic activator of ERK signalling in non-neuronal cells, with no mention of TrkB or TrkC at all.
- A fully resolved chemical identity confirmed by the discovery authors themselves
- Reproducible activation of ERK signalling, whatever the route
- No safety data or toxicology
- A chemotype with a long history of non-selective biological activity, never screened for selectivity here
Mechanism
The claimed mechanism is co-activation of and TrkC, with a distinctive relationship to the p75 neurotrophin receptor, producing neuronal survival and process outgrowth [1].
⚠️ Chemically the molecule is a triarylmethane: a chlorophenyl-methane bridge joining two anilines each bearing two hydroxyethyl groups. That is the leuco-base architecture of the malachite green and crystal violet dye family. Compounds of this class are redox-active and frequently interfere with assays, which materially lowers the likelihood that a screening hit from it is a selective receptor tyrosine kinase . This is a chemical observation rather than a refutation, and it is stated because it changes how the primary result should be weighed.
⚠️ It has no ChEMBL record, so no curated activity data exists for it anywhere.
⚠️ Most tellingly, the recent literature has drifted away from the stated mechanism. The compound now appears mostly as a generic ERK activator in cells unrelated to the nervous system, with no reference to either neurotrophin receptor, and one paper reassigns its activity to a completely different protein.
⚠️ The whole class this belongs to rests on a contested claim. Nearly all the positive primary data for direct activation of by small molecules comes from one research group, and at least three independent teams have failed to reproduce receptor-level activation. Two of those were industrial drug-discovery groups using quantitative assays with a monoclonal antibody as a positive control [2][3], and a later review reached the same conclusion [4]. Downstream biological effects are often reproducible; the step in dispute is whether they happen by binding the receptor.
Practical note from the original methods: it needs dilute acid to dissolve for cell work and a surfactant vehicle for injection, so aqueous solubility is poor.
receptor fingerprint
ERK signallingActivates
and TrkC receptorsClaimed co-activator
Evidencehow good the literature is
One discovery paper and a subsequent literature that mostly ignores its stated mechanism.
The discovery paper reports it as a TrkB and TrkC co-activator with effects on neuronal survival and process outgrowth [1]. Its subject identity is unambiguous; the compound and its database identifier are named in the record itself.
⚠️ What happened afterwards is the informative part. Searching the compound returns a few dozen records, and the recent ones are overwhelmingly not neurotrophin papers; the molecule is used as a convenient ERK activator in non-neuronal systems without reference to the receptors it was introduced for.
⚠️ There is no clinical trial, no sponsor, no human pharmacokinetic data and no independent confirmation of the receptor-level claim.
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
No human exposure, no toxicology and no safety study.
⚠️ The chemotype warrants specific mention. Triarylmethane dyes and their leuco forms have a long history of biological activity that is neither selective nor benign, and no selectivity screening has been published for this molecule.
History
The compound came from the same laboratory and the same screening approach as LM22A-4, published in 2016 as a dual-receptor version of the idea. It has never been developed, and its practical afterlife has been as a laboratory reagent for a purpose unrelated to the one it was designed for.
Resources
This entry is here for reference.
Research
- 2014first citedA monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease
- 2021most recentDo Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Publis…
- 1.A small molecule TrkB/TrkC neurotrophin receptor co-activator with distinctive effects on neuronal survival and process outgrowth
- 2.A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease
- 3.Multiplex quantitative assays indicate a need for reevaluating reported small-molecule TrkB agonists
- 4.Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists.
4 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Why does the chemistry matter so much here?
Because triarylmethanes are one of the classic false-positive chemotypes in screening. They are redox-active and interfere with many assay formats, so a hit from this class needs stronger confirmation than usual, not weaker. That is not proof this molecule does nothing; it is a reason the original result needed independent replication that never came.
Limitations of the evidence
- A triarylmethane, the leuco architecture of the malachite green and crystal violet dye family, a promiscuous and assay-interfering class
- Recent literature uses it as a generic ERK activator with no reference to TrkB or TrkC
- One recent paper reassigns its activity to a different protein entirely
- No ChEMBL record and therefore no curated activity data
- The class-level receptor claim failed independent replication
- Poor aqueous solubility; needs dilute acid or a surfactant vehicle
- No human data, no trial and no independent confirmation
Adverse effects
- No safety data or toxicology
- A chemotype with a long history of non-selective biological activity, never screened for selectivity here